PT  - JOURNAL ARTICLE
AU  - RACHEL A. CROSSLEY
AU  - ALYSSA MATZ
AU  - TERRY DEW
AU  - ASHLEY KALINAUSKAS
AU  - NICOLE FAUCETTE
AU  - BRAD POFF
AU  - LAWRENCE K. SILBART
AU  - MARK A. SUCKOW
TI  - Safety Evaluation of Autologous Tissue Vaccine Cancer Immunotherapy in a Canine Model
AID  - 10.21873/anticanres.13275
DP  - 2019 Apr 01
TA  - Anticancer Research
PG  - 1699--1703
VI  - 39
IP  - 4
4099  - http://ar.iiarjournals.org/content/39/4/1699.short
4100  - http://ar.iiarjournals.org/content/39/4/1699.full
SO  - Anticancer Res2019 Apr 01; 39
AB  - Background/Aim: Previous work in rodent models showed that an autologous tissue vaccine is both a safe and effective approach for treating cancer; however, as a translational step, safety must first be evaluated in a more clinically-relevant model. Materials and Methods: An autologous immunotherapy produced from resected tumors, was evaluated in a clinically-relevant canine model to assess safety. Ninety-three dogs with spontaneously occurring tumors received vaccination with inactivated autologous tumor tissue combined with an adjuvant of particulate porcine small intestinal submucosa extracellular matrix (SIS-ECM). Patients were followed to assess the occurrence of adverse events, overall survival, and tumor recurrence and/or metastasis. Results: A small number (12%) of patients experienced limited, mild pyrexia, injection site swelling, or lethargy, all resolving without clinical intervention. Conclusion: Autologous whole cell cancer immunotherapy can be used safely in the canine model of cancer and represents a safe approach for the treatment for cancer.